Wouter Joustra
Director/Board Member at ENGENE HOLDINGS INC.
Profile
Wouter Joustra is currently a Director at Aiolos Bio, Inc., Director at enGene Holdings, Inc., and General Partner at Forbion Capital Partners Management Holding BV.
Previously, he held positions as an Executive Director-Life Sciences Franchise at Kempen & Co. USA, Inc., Director at Gyroscope Therapeutics Ltd., Independent Director at VectivBio Holding AG, Non-Executive Director at Gyroscope Therapeutics Holdings Plc, and Non-Independent Director & Investment Director at Forbion European Acquisition Corp.
Mr. Joustra has an undergraduate degree from the University of Nebraska and undergraduate and graduate degrees from the University of Groningen.
Wouter Joustra active positions
| Companies | Position | Start |
|---|---|---|
| ENGENE HOLDINGS INC. | Director/Board Member | 2024-05-14 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2019-09-30 |
Former positions of Wouter Joustra
| Companies | Position | End |
|---|---|---|
| VECTIVBIO HOLDING AG | Director/Board Member | 2023-06-25 |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2022-02-16 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 2021-10-07 |
Kempen & Co. USA, Inc.
 Kempen & Co. USA, Inc. Investment Banks/BrokersFinance Founded in 1995, Kempen & Co., USA, Inc. is an SEC-registered broker/dealer located in New York City. The firm is a wholly-owned 100% subsidiary of Kempen & Co. NA, an Amsterdam-based merchant bank that was founded in 1903. Kempen & Co. USA focuses on Benelux equities (home-market), European real estate equities, European clean Technology and biotechnology equities. The firm's research includes equity and property reports, daily comments, technical analysis, strategic overviews and complete sector reports. Kempen & Co. USA provides services to institutional clients. The firm is a member of FINRA. | Corporate Officer/Principal | - |
| FORN EUROPAR | Chief Investment Officer | - |
Training of Wouter Joustra
| University of Groningen | Graduate Degree |
| University of Nebraska | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Private companies | 6 |
|---|---|
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
Kempen & Co. USA, Inc.
Kempen & Co. USA, Inc. Investment Banks/BrokersFinance Founded in 1995, Kempen & Co., USA, Inc. is an SEC-registered broker/dealer located in New York City. The firm is a wholly-owned 100% subsidiary of Kempen & Co. NA, an Amsterdam-based merchant bank that was founded in 1903. Kempen & Co. USA focuses on Benelux equities (home-market), European real estate equities, European clean Technology and biotechnology equities. The firm's research includes equity and property reports, daily comments, technical analysis, strategic overviews and complete sector reports. Kempen & Co. USA provides services to institutional clients. The firm is a member of FINRA. | Finance |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Wouter Joustra
